TENX - Tenax Therapeutics, Inc.
About Tenax Therapeutics, Inc. (https://www.tenaxthera.com)
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Christopher T. Giordano | Chief Executive Officer, President & Director | 1975 | $813,633 USD |
| Stuart Rich | Chief Medical Officer & Director | 1950 | $490,217 USD |
| Thomas A. McGauley | Principal Financial Officer & Principal Accounting Officer | 1973 | $475,498 USD |
| Doug Randall | Chief Business Officer | – | – |
| Douglas Hay | Executive Vice President of Regulatory Affairs | – | – |
| So-Young Kim | Executive Vice President of Clinical Development & Strategy | – | – |
| Thomas R. Staab | Chief Financial Officer | 1968 | – |
| Timothy G. Healey | Chief Commercial Officer | 1966 | – |